乾癬治療薬の臨床開発動向

Abstract

Overview of Clinical Intelligence Report Series

Austin Research Analytics Group' s (ARAG) Clinical Intelligence Report Series provides clients within the pharmaceutical and biotechnology industry with detailed competitive information to facilitate key analysis and decision-making. Clients utilize the report as an resource to support key decisions including:

• Analyzing the overall depth and breadth of the competitive landscape within a therapeutic area
• Assessing target product profiles of key current and future competitors
• Benchmarking competitor clinical trial designs and results
• Developing clinical analogues to support go-no-go decisions
• Identifying clinical hurdles posed by competitors
• Designing clinical trials more effectively to maximize a product' s penetration

Reports contain synthesized information and analysis of clinical development activities for key marketed and pipeline products within multiple therapeutic categories and generally include the following data points:

• Product Overview: Mechanism of Action, Developing Companies, Indications and Phase of Development.
• Clinical Trial Assessments: Detailed evaluations of completed and ongoing competitor studies that capture key elements of the study protocol including:
  • Trial design
  • Start and end dates
  • Study size and patient type
  • Number of participating sites
  • Dosing regimen
  • Endpoints
  • Safety and efficacy results

Table of Contents

Section 1: Executive Summary

• Psoriasis Disease Overview
• Classification of Psoriasis
• Disease Epidemiology: U.S. & European Prevalence
• Disease Epidemiology-Patient Segmentation
• Psoriasis Treatment Paradigm
• Conventional Psoriasis Therapies
• Overview of Competitive Landscape
• Ongoing Psoriasis Clinical Trials

Section 2: The Current Market Leaders in Psoriasis

• Enbrel (etanercept)
• Remicade (infliximab)
• Humira (adalimumab)
• Raptiva

Section 3: Future Competitive Threats

• CNTO-1275
• Golimumab (CNTO-148)
• ABT-874
• Cimzia
• Zanolimumab

Section 4: Early Stage Development Programs: Products on the Radar

• BMS-582949
• Apremilast
• BIRT 2584XX
• AMG-714
• BCX-4208
• MEDI-545

Section 5: Appendix

• Disclaimer
• Report Licensing